In-Situ NMR Study of Activated Peroxide Decontamination of ¹³C-enriched HD

Mark Winemiller, ECBC; Kelly Maguire, ECBC; George W. Wagner, ECBC; Mark D. Brickhouse, ECBC; Fred Berg, ECBC; Jennifer Edwards, GEO-CENTERS, Inc.; Bill Creasy, EAI Corp.

Edgewood Chemical Biological Center



maintaining the data needed, and c including suggestions for reducing	election of information is estimated to completing and reviewing the collect this burden, to Washington Headqu uld be aware that notwithstanding ar OMB control number.	ion of information. Send comments arters Services, Directorate for Infor	regarding this burden estimate of mation Operations and Reports	or any other aspect of the property of the contract of the con	nis collection of information, Highway, Suite 1204, Arlington		
1. REPORT DATE 19 NOV 2003		2. REPORT TYPE N/A		3. DATES COVE	RED		
4. TITLE AND SUBTITLE	5a. CONTRACT NUMBER						
In-Situ NMR Study of Activated Peroxide Decontamination of 13C-enriched HD				5b. GRANT NUMBER			
13C-emicieu 11D				5c. PROGRAM ELEMENT NUMBER			
6. AUTHOR(S)					5d. PROJECT NUMBER		
					5e. TASK NUMBER		
					5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Edgewood Chemical Biological Center				8. PERFORMING ORGANIZATION REPORT NUMBER			
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)					10. SPONSOR/MONITOR'S ACRONYM(S)		
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited							
	otes 51, Proceedings of t Research, 17-20 No						
14. ABSTRACT							
15. SUBJECT TERMS							
16. SECURITY CLASSIFIC	17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON				
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified	UU	13	RESI UNSIBLE FERSUN		

Report Documentation Page

Form Approved OMB No. 0704-0188



Background

Base-activated hydrogen peroxide formulations are under development as broad spectrum decontaminants for chemical and biological weapons. In the decontamination of nerve agents such as VX and GD, these formulations produce the perhydrolysis products ethyl methylphosphonic acid (EMPA) and pinacolyl methylphosphonic acid (GD acid), respectively. The decontamination of distilled mustard (HD) produces a more complex mixture of products, which are not readily characterizable by any single analytical technique.





Analytical Results

Initial GC-MS analysis of reaction masses produced by base-activated peroxide decontamination of HD identified bis(2-chloroethyl) sulfoxide (mustard sulfoxide) as a major product. However, in-situ NMR analysis of ¹³C-enriched HD decontamination in baseactivated peroxide formulations shows the formation of additional reaction products, and substantial change in the distribution of reaction products in the first 24 hours after decontamination. ¹³C-enrichment allows the HD products to be clearly distinguished from the components of the decontamination formulation, and facilitates identification of the reaction products. The identification of dehydrohalogenated and oxidized HD products will be discussed.

T = 1 min.

Preliminary Identification of Initial HD Degradation Products in MDF-1 by GC-AED





T = 60 min.







Experimental


- In-situ NMR experiments performed with 20mg of ¹³C-enriched HD in 1 gram of decon. solution in 5mm NMR tube
- Agent operations carried in accordance with Surety SOP CR8-0SP035, The NMR Experiment for Liquids and Solids
- Tube maintained at 25 °C
- Degradation of mustard recorded by ¹³C NMR analysis at various time intervals.
- NMR spectra acquired on Varian 600 MHz narrow bore NMR, E3300, Rm 2
- 5 mm Broadband, triple axis gradient PFG probe
- Gradient shimming used for expedited shimming on nondeuterated samples


Initial Time Point ¹³C NMR Spectrum of ¹³C-enriched HD in MDF-1, Showing HD Methylene Peaks @ 32.5 and 31.5 ppm

















¹³C-enriched HD in MDF1 @ RT vs. time












Comparisons ¹³C NMR spectra of ¹³C-enriched HD in MDF1 @ RT to reference compounds







Tentative assignments for the MDF-1 experiment

$$1 = \bigcup_{\text{Cl}} \bigcup_{\text{S}} \bigcup_{\text{Cl}} \bigcup_{\text{Cl}} \bigcup_{\text{1-Chloro-2-(2-chloro-ethanesulfinyl)-ethane}} \bigcup_{\text{Cl}} \bigcup_{\text{Cl}}$$

$$2 = \underbrace{\begin{array}{c} 0 \\ 0 \\ 0 \end{array}}_{\text{CI}}$$
(2-Chloro-ethanesulfonyl)-ethene

$$3 = \underbrace{\begin{array}{c} 0 \\ 1 \\ 1 \\ 1 \end{array}}_{\text{Ethene sulfinyl-ethene}}$$

4 = unknown carbonyl signals




Initial Results


- 1. First immediate products are the mustard sulfoxide (HDO, 1) and 2-chloroethyl vinylsulfoxide (2)
- 2. By 87 min can see small signals for the divinyl sulfoxide (3) and small signals that represent the carbonyl species (4)
- 3. By 1125 minutes (18 hrs. 45 min) the carbonyl species (4) dominate and further resolve one week later (8/18/2003)
- 4. Preliminary standards synthesis and 2-D NMR analyses indicate that species (4) is a carboxylic acid derivative of HD sulfoxide




Reference Sample of Dicarboxylic Acid Derivative of HD Sulfoxide Matches Two Major Product Peaks in MDF-1 Reaction Mass



The ¹³C NMR Spectra ¹³C-enriched HD in MDF-1 and in EFT-2 After 7 Days at RT Indicate at Least One Common Carboxylic Acid Product, but the EFT Reaction Mass Contains at Least Two Additional, Novel Products





MDF-1

EFT-2



Table 1: Toxic Properties of HD, HDO, HDO₂, 2-Chloroethylvinyl sulfoxide and Divinylsulfoxide

	Toxicity, LD ₅₀ (mouse, mg/kg)	Vesicant Action	Relative Hydrolysis Rate
HD HDO HDO ₂	125 ^a ; 8.6 ^b 125 ^a 105 ^a ; 50 ^b	most irritating ^c ; severe ^d scarcely irritating ^c ; none ^d slightly less than HD ^c ; severe ^d	Fast (50% in 10 min, 20°C) ^c Not hydrolyzed, even at 100°C ^c Slow (55.9% in 150 min, 22°C) ^c
2-chloroethyl vinyl sulfoxide	100 (LD _{LO}) ^e	Not available	Not available
Divinyl sulfoxide	50 (LD _{LO}) ^e	Not available	Not available

^aSubcutaneous, reference 10. ^bIntravenous, reference 12. ^cReference 10. ^dReference 11.

10. Lawson, W. E.; Reid, E. E. J. Am. Chem. Soc. 1925, 47, 2821-2836.

11. Anslow, W. P., Jr.; Karnofsky, D. A.; Val Jager, B.; Smith, H. W. J. Pharmacol. Exp. Therapeutics 1948, 93, 1-9.

12. (a) Drago, R. S.; Frank, K. M.; Wagner, G. W.; Yang, Y.-C. In the *Proc. 1997 ERDEC Sci. Conf. Chem. Biol. Def. Res., ERDEC-SP-063*; U.S. Army Edgewood Research, Development and Engineering Center, 1998, pp. 341-342. (b) Wagner, G. W.; Yang, Y.-C. In the *Proc. 1998 ERDEC Sci. Conf. Chem. Biol. Def. Res., ERDEC-SP-004*; U.S. Army Edgewood Research, Development and Engineering Center, 1999, pp. 285-291.

13. NDRC. Volume 9-4-1-9. Washington, DC: Office of Scientific Research and Development, National defense Research Committee, 1943

e Oral, Reference 13.